Cyramza 500 MG/50 ML vial 50ML
Ended Awarded
- Contract number
- SPE2DR26FSBZ7
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $31,466
Award facts
- Contract value 100% obligated
- $31,466.22 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $31,466.22 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of CYRAMZA 500 mg/50 mL vials. This firm fixed-price delivery order was issued on November 17, 2025, with an ultimate completion date of December 9, 2025, and carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The order will be fulfilled at the contractor's location in Park Ridge, Illinois, and represents a discrete pharmaceutical supply requirement within the broader federal military medical supply chain.
This delivery order is issued under DMS Pharmaceutical Group's recently awarded Indefinite Delivery Contract (IDC) under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for recurring pharmaceutical needs of Department of Defense healthcare facilities worldwide. The underlying IDC, awarded November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established performance history across multiple therapeutic categories and product lines, including oncology treatments, biologics, vaccines, and specialty pharmaceuticals, positions the company as a critical supplier for federal military medical operations.
Quick answers
Who was awarded contract SPE2DR26FSBZ7?
SPE2DR26FSBZ7 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FSBZ7 worth?
The government has obligated $31,466 on SPE2DR26FSBZ7.
Is contract SPE2DR26FSBZ7 an order under another contract?
Yes. SPE2DR26FSBZ7 is a delivery order under SPE2DR25D9316, an indefinite delivery contract.
Was contract SPE2DR26FSBZ7 competed?
The extent of competition for SPE2DR26FSBZ7 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award